Biocon Q3FY23 Earnings: Revenue up 36%, PAT falls 25% YoY
With a market capitalization of ₹28,202.09 Cr, Biocon Ltd. is a large-cap company that engages in the pharmaceutical industry.
Source: livemint.com
Page 3 - Generic Formulations News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Generic Formulations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Generic Formulations Today - Breaking & Trending Today
Biocon Q2FY23 Revenue at Rs 2,384 Cr., Up 23 percent; Core EBITDA at Rs 816 Cr., Up 34 percent Gross R&D Spend at Rs 252 Crore, Up 52 percent
Bengaluru (Karnataka) [India], November 15 (ANI/NewsVoir): Biocon Ltd. (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced its consolidated financial results for the second quarter ended September 30, 2022. Leadership Comments Biocon Group "We reported a strong consolidated revenue growth of 23 per cent YoY for Q2FY23 at Rs. 2,384 Crore driven by 34 per cent growth in Biosimilars, 26 per cent in Research Services and 18 per cent in the Generics business. Our Gross R&D spends increased by 52 per cent YoY this quarter to Rs. 252 Crore re...
Source: laosnews.net
Viatris Inc. and Biocon Biologics Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes
Share this article Share this article PITTSBURGH and BENGALURU, India, July 28, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) and Biocon Biologics Ltd. (a subsidiary of Biocon Ltd.) today announced that the U.S. Food and Drug Administration (FDA) has approved Semglee ® (insulin glargine-yfgn) injection as the first interchangeable biosimilar product under the 351(k) regulatory pathway. Biocon Biologics Viatris CEO Michael Goettler commented: "We are extremely proud to achieve the industry's first approval of an interchangeable biosimilar product in the U.S., which will help broaden acces...
Source: prnewswire.com